FDA-approved2Evidence: Large human trialsInfections

Enfuvirtide1,2

Also called Fuzeon1,2

Key takeaway

Enfuvirtide is a synthetic peptide that blocks HIV-1 from fusing with human cells. It is the active ingredient in Fuzeon, which FDA approved in 2003.1,2,3 In the randomized TORO 2 trial of 512 people with drug-resistant HIV-1, adding enfuvirtide to an optimized drug combination lowered the amount of virus in the blood more than the combination alone over 24 weeks.3 Drugs@FDA now lists Fuzeon as discontinued.2

Enfuvirtide at a glance

What it isA synthetic peptide HIV-1 fusion inhibitor, also recorded as DP-178 and T-20 in FDA’s substance registry.1,3
FDA statusFDA-approved, but discontinued. Drugs@FDA lists Fuzeon, NDA 021481, with an original approval date of March 13, 2003, and lists the product as discontinued.2
Human evidenceLarge randomized Phase 3 trials, including TORO 2 in 512 people with drug-resistant HIV-1, published in 2003.3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is enfuvirtide?

Enfuvirtide is a synthetic peptide that FDA’s substance registry also records as DP-178 and T-20, and under the brand name Fuzeon.1

In the United States it is the active ingredient of Fuzeon, approved under NDA 021481, according to Drugs@FDA.2

How does enfuvirtide work?

The TORO 2 investigators describe enfuvirtide as a fusion inhibitor: it acts against HIV-1 at the step where the virus fuses with a cell, a different target from the other classes of HIV drugs their patients had already received.3

What do human studies show?

TORO 2 randomized 512 people who had taken all three earlier classes of HIV drugs, had resistance to them, or both, to an optimized combination with or without enfuvirtide.3

After 24 weeks, the amount of virus in the blood fell more with enfuvirtide added, and CD4 immune cell counts rose more (by about 66 versus 38 cells per cubic millimetre), according to the trial report.3

What the evidence base contains

  • Large randomized human trial TORO 2: a randomized Phase 3 trial of 512 people with drug-resistant HIV-1 in Europe and Australia, comparing an optimized drug combination with and without enfuvirtide for 24 weeks (2003).3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is enfuvirtide FDA-approved?

Yes, but the product is no longer sold. Drugs@FDA lists Fuzeon, application NDA 021481, with an original approval date of March 13, 2003, and lists Fuzeon as discontinued.2

The sources reviewed here do not report that FDA has withdrawn the approval.2

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list enfuvirtide.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Enfuvirtide is not among them.5,6

Timeline

  1. The TORO 2 trial of enfuvirtide in 512 people with drug-resistant HIV-1 is published.3
  2. FDA approves Fuzeon, NDA 021481, according to Drugs@FDA.2

What is still unknown?

Its longer-term effect: TORO 2 compared the treatments over 24 weeks.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Enfuvirtide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Enfuvirtide are a bounded selection, not every registration or paper about Enfuvirtide. For the years before Enfuvirtide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Enfuvirtide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Enfuvirtide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Fuzeon for HIV-1; discontinued. In a randomized trial of 512 people with drug-resistant HIV-1, adding enfuvirtide lowered virus levels more than an optimized combination alone. Enfuvirtide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Enfuvirtide?

FDA-approved as Fuzeon for HIV-1; discontinued. In a randomized trial of 512 people with drug-resistant HIV-1, adding enfuvirtide lowered virus levels more than an optimized combination alone. Enfuvirtide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
16
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Literature metadata · source date October 11, 2026

Enfuvirtide.↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Enfuvirtide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

49Selected dated records
55Connected citations
16Populated source years2003–2026
3/4Record lanes present

Registered human studies

Trial composition

22 of 22 selected trial records include at least one phase value; 22 of 22 include a status value in the retained structured contract.

PhasesPhase 2 7Phase 3 6Phase 4 5Phase 1 3Not applicable 2Early Phase 1 1
Status at observationCompleted 22

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 24Review 12Clinical Trial 7Research Support, Non-U.S. Gov't 7Multicenter Study 3Randomized Controlled Trial 3Clinical Trial, Phase II 2Clinical Trial, Phase III 2Comparative Study 2Controlled Clinical Trial 2Clinical Trial, Phase I 1Comment 1Consensus Statement 1Editorial 1Newspaper Article 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
49

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 49 dated records

Research hub

Explore the Enfuvirtide evidence record

Open all 49 records →
49Dated records
3Evidence types
49Cited public sources
16Source years

Change ledger

Recently changed for Enfuvirtide

Open all 49 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00001118

PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.

PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002228

PeptideScanner retained ClinicalTrials.gov record NCT00002228 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002239

PeptideScanner retained ClinicalTrials.gov record NCT00002239 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-11-15, and PeptideScanner's reviewed identity mapping was enfuvirtide.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2005
Evidence lane
Clinical trials

Official-source collections

Source records for Enfuvirtide

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel.Drug delivery and translational research · 2023 04 29
  2. Enfuvirtide biosynthesis in thermostable chaperone-based fusion.Biotechnology reports (Amsterdam, Netherlands) · 2022 05 14
  3. Enfuvirtide: from basic investigations to current clinical use.Expert opinion on pharmacotherapy · 2010 Nov
Explore all selected literature →
ClinicalTrials.gov22

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT00302822Registry update April 7, 2026 · completed at observation
  2. NCT00120367Registry update April 2, 2026 · completed at observation
  3. NCT01836068Registry update November 23, 2021 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span March 13, 2003 to October 11, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 49

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Enfuvirtide.↗

    PubMed lists PMID 14664654 in Drugs as Journal Article, Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.↗

    PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00302822↗

    PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00120367↗

    PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗

  5. Literature metadata

    [Spanish recommendations for proper use of enfuvirtide].↗

    PubMed lists PMID 17288910 in Enfermedades infecciosas y microbiologia clinica as Consensus Statement, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.↗

    PubMed lists PMID 20001856 in The Journal of infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2010-01-15 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel.↗

    PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Enfuvirtide biosynthesis in thermostable chaperone-based fusion.↗

    PubMed lists PMID 35646620 in Biotechnology reports (Amsterdam, Netherlands) as Journal Article, with publication-date metadata of 2022-05-14 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.↗

    PubMed lists PMID 17389560 in Journal of clinical pharmacology as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT01836068↗

    PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00537394↗

    PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT00001118↗

    PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Enfuvirtide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: FUZEON (enfuvirtide), NDA 021481 · original approval March 13, 2003 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia (2003) · PMID 12773645 ↗

    The New England Journal of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026